FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754332188> ?p ?o ?g. }

• W2754332188 abstract "<h3>Background</h3> In MOBILITY (NCT01061736), SC sarilumab (150 or 200 mg q2w) + MTX demonstrated efficacy in adults with RA and inadequate response to MTX. The most common TEAEs were infections, neutropenia, injection site reactions, and increased transaminases. <h3>Objectives</h3> To examine association between clinical response and radiographic progression and functional response (HAQ-DI) in MOBILITY. <h3>Methods</h3> In this post hoc analysis, associations between HAQ-DI and clinical efficacy categories (CDAI, DAS28-CRP, SDAI, and Boolean-based ACR/EULAR remission) were tested at wk 16. Trend for change from baseline (BL) in HAQ-DI across response categories was assessed using the Jonckheere-Terpstra test. <h3>Results</h3> Regardless of definition, percentage achieving remission (CDAI ≤2.8, DAS28-CRP <2.6, SDAI ≤3.3) or no x-ray progression was higher with sarilumab vs Pbo (<i>P</i><0.05). Overall, there was a significant trend between magnitude of clinical response at wk 16 and improvement in physical function (Table). This trend was also observed for radiographic progression (mTSS change from BL), regardless of cutoff (≤0.5 and ≤0). In patients achieving remission, there was a numerically greater improvement in HAQ-DI with sarilumab vs placebo (Pbo). Even if patients did not achieve remission or LDA, the sarilumab group had generally greater numerical improvements in HAQ-DI vs Pbo. <h3>Conclusions</h3> Achieving LDA or remission, or absence of radiographic progression, was associated with overall greater improvement in physical function. Irrespective of whether patients achieved remission or LDA, sarilumab + MTX showed greater improvements in HAQ-DI than Pbo + MTX. <h3>Acknowledgements</h3> This study was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Editorial support was provided by MedThink SciCom and funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. <h3>Disclosure of Interest</h3> M. Genovese Grant/research support from: Roche, Sanofi, GlaxoSmithKline, R-Pharma, RuiYi, and Bristol-Myers Squibb, Consultant for: Roche, Sanofi, GlaxoSmithKline, R-Pharma, RuiYi, and Bristol-Myers Squibb, H. van Hoogstraten Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, W. Kampman Shareholder of: Regeneron Pharmaceuticals, Inc, Employee of: Regeneron Pharmaceuticals, Inc, S. Jayawardena Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, T. Huizinga Consultant for: Sanofi, Roche, and Abblynx." @default.
• W2754332188 created "2017-09-25" @default.
• W2754332188 creator A5000196410 @default.
• W2754332188 creator A5004560391 @default.
• W2754332188 creator A5055911487 @default.
• W2754332188 creator A5065173509 @default.
• W2754332188 creator A5090529679 @default.
• W2754332188 date "2017-06-01" @default.
• W2754332188 modified "2023-09-27" @default.
• W2754332188 title "FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis" @default.
• W2754332188 doi "https://doi.org/10.1136/annrheumdis-2017-eular.3513" @default.
• W2754332188 hasPublicationYear "2017" @default.
• W2754332188 type Work @default.
• W2754332188 sameAs 2754332188 @default.
• W2754332188 citedByCount "0" @default.
• W2754332188 crossrefType "proceedings-article" @default.
• W2754332188 hasAuthorship W2754332188A5000196410 @default.
• W2754332188 hasAuthorship W2754332188A5004560391 @default.
• W2754332188 hasAuthorship W2754332188A5055911487 @default.
• W2754332188 hasAuthorship W2754332188A5065173509 @default.
• W2754332188 hasAuthorship W2754332188A5090529679 @default.
• W2754332188 hasBestOaLocation W27543321881 @default.
• W2754332188 hasConcept C126322002 @default.
• W2754332188 hasConcept C142724271 @default.
• W2754332188 hasConcept C1862650 @default.
• W2754332188 hasConcept C204787440 @default.
• W2754332188 hasConcept C27081682 @default.
• W2754332188 hasConcept C2776694085 @default.
• W2754332188 hasConcept C2777063308 @default.
• W2754332188 hasConcept C2777575956 @default.
• W2754332188 hasConcept C2781059491 @default.
• W2754332188 hasConcept C67761136 @default.
• W2754332188 hasConcept C71924100 @default.
• W2754332188 hasConceptScore W2754332188C126322002 @default.
• W2754332188 hasConceptScore W2754332188C142724271 @default.
• W2754332188 hasConceptScore W2754332188C1862650 @default.
• W2754332188 hasConceptScore W2754332188C204787440 @default.
• W2754332188 hasConceptScore W2754332188C27081682 @default.
• W2754332188 hasConceptScore W2754332188C2776694085 @default.
• W2754332188 hasConceptScore W2754332188C2777063308 @default.
• W2754332188 hasConceptScore W2754332188C2777575956 @default.
• W2754332188 hasConceptScore W2754332188C2781059491 @default.
• W2754332188 hasConceptScore W2754332188C67761136 @default.
• W2754332188 hasConceptScore W2754332188C71924100 @default.
• W2754332188 hasLocation W27543321881 @default.
• W2754332188 hasOpenAccess W2754332188 @default.
• W2754332188 hasPrimaryLocation W27543321881 @default.
• W2754332188 hasRelatedWork W1977601919 @default.
• W2754332188 hasRelatedWork W2024079807 @default.
• W2754332188 hasRelatedWork W2071054988 @default.
• W2754332188 hasRelatedWork W2096960896 @default.
• W2754332188 hasRelatedWork W2158058290 @default.
• W2754332188 hasRelatedWork W2401514108 @default.
• W2754332188 hasRelatedWork W2414220780 @default.
• W2754332188 hasRelatedWork W2775812515 @default.
• W2754332188 hasRelatedWork W2783466784 @default.
• W2754332188 hasRelatedWork W70445611 @default.
• W2754332188 isParatext "false" @default.
• W2754332188 isRetracted "false" @default.
• W2754332188 magId "2754332188" @default.
• W2754332188 workType "article" @default.